|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM259980404 |
| 003 |
DE-627 |
| 005 |
20250220024113.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2016 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2016.04.008
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0866.xml
|
| 035 |
|
|
|a (DE-627)NLM259980404
|
| 035 |
|
|
|a (NLM)27140729
|
| 035 |
|
|
|a (PII)S1521-6616(16)30067-5
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Shen, Long
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Central role for marginal zone B cells in an animal model of Sjogren's syndrome
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.03.2017
|
| 500 |
|
|
|a Date Revised 25.03.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2016 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Patients with Sjogren's syndrome (SS) have been shown to have abnormal B cell function and increased numbers of marginal zone B cells (MZB and MZB precursors. The current studies utilized the Interleukin 14 alpha transgenic mouse model (IL14aTG) for SS to investigate the roles of marginal zone B cells (MZB) of the innate immune system in the pathophysiology of the disease. Eliminating MZB from IL14aTG mice by B cell specific deletion of RBP-J resulted in complete elimination of all disease manifestations of SS. Mice had normal salivary gland secretions, negative autoantibodies and normal histology of the salivary and lacrimal glands compared to IL14aTG mice at the same time points. In contrast, eliminating B1 cells by deleting btk did not ameliorate the disease. Therefore, MZB are critical for the development of SS
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Autoantibodies
|2 NLM
|
| 650 |
|
7 |
|a Interleukins
|2 NLM
|
| 650 |
|
7 |
|a TXLNA protein, mouse
|2 NLM
|
| 650 |
|
7 |
|a Vesicular Transport Proteins
|2 NLM
|
| 700 |
1 |
|
|a Gao, Chun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Suresh, Lakshmanan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xian, Zhenhua
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Song, Nannan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chaves, Lee D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Meixing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ambrus, Julian L
|c Jr
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 168(2016) vom: 21. Juli, Seite 30-36
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:168
|g year:2016
|g day:21
|g month:07
|g pages:30-36
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2016.04.008
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 168
|j 2016
|b 21
|c 07
|h 30-36
|